Atnaujinkite slapukų nuostatas

Atlas of Contrast-Enhanced Mammography 2021 ed. [Minkštas viršelis]

  • Formatas: Paperback / softback, 456 pages, aukštis x plotis: 279x210 mm, weight: 1173 g, 161 Illustrations, color; 340 Illustrations, black and white; XX, 456 p. 501 illus., 161 illus. in color., 1 Paperback / softback
  • Išleidimo metai: 06-Jan-2022
  • Leidėjas: Springer Nature Switzerland AG
  • ISBN-10: 3030562654
  • ISBN-13: 9783030562656
Kitos knygos pagal šią temą:
  • Formatas: Paperback / softback, 456 pages, aukštis x plotis: 279x210 mm, weight: 1173 g, 161 Illustrations, color; 340 Illustrations, black and white; XX, 456 p. 501 illus., 161 illus. in color., 1 Paperback / softback
  • Išleidimo metai: 06-Jan-2022
  • Leidėjas: Springer Nature Switzerland AG
  • ISBN-10: 3030562654
  • ISBN-13: 9783030562656
Kitos knygos pagal šią temą:

This superbly illustrated atlas serves as a basic introduction to contrast-enhanced mammography (CEM), a breakthrough functional breast imaging modality, which is rapidly growing. This book is an essential guide for the latest developments with correlative findings, practical interpretation tips, physics, and information on how contrast mammography differs from conventional 2D and 3D Full Field of View digital mammography (FFDM). It includes:

·         over 1000 high-quality 2D, 3D and recombined contrast mammography images 

representing the spectrum of breast imaging

·         findings obtained in the full range of benign, pre-malignant and malignant conditions, including artefacts and postoperative changes, presented with high-quality illustrations from case examples

·         image interpretation tips using mammographic and DCE-MRI descriptors of the BI-RADS lexicon to effectively read and interpret this advanced imaging modality

·         practical tips to interpret this new modality and how it is used as an adjunct to 2D mammography

·         details on how integration of contrast-enhanced mammography drastically changes lesion work-up and overall workflow in the department

·         "imaging pearls" boxes offering interpretation tips for expert clinical guidance

·         a case on the recently introduced CEM guided biopsy procedure

 

The book’s target audience consists of diagnostic radiologists, residents, fellows, technologists and clinicians involved in the care of breast cancer patients, including surgeons and oncologists. The goal is to provide a concise introduction to CEM and to lead to enhanced interpretation and better patient staging prior to surgery.   


 

 


1 Introduction
1(10)
1.1 The Problem of "Structural Noise"
3(1)
1.2 Imaging Angiogenesis
4(1)
1.3 Subtraction Imaging
5(3)
1.3.1 Radiation Doses in Contrast Mammography
7(1)
1.3.2 Current Research and Future Considerations
7(1)
1.4 Conclusions
8(1)
References
8(3)
2 Interpretation
11(26)
2.1 Final Assessment Categories and Management
11(1)
2.2 Breast Composition
12(1)
2.3 Background Parenchymal Enhancement (BPE)
12(3)
2.4 CEM Lexicon
15(20)
2.4.1 Focus
15(1)
2.4.2 Mass
15(6)
2.4.3 Non-mass Enhancement (NME)
21(1)
2.4.4 Calcifications
22(3)
2.4.5 Architectural Distortion
25(10)
References
35(2)
3 Indications
37(86)
3.1 Inconclusive Findings in Conventional Breast Imaging
37(14)
3.1.1 Assessment of Calcifications
37(14)
3.2 Preoperative Staging
51(20)
3.2.1 Case 1
51(7)
3.2.2 Case 2
58(6)
3.2.3 Case 3
64(7)
3.3 Evaluation of Patients with Unknown Primary Cancer
71(11)
3.3.1 Case 1
71(6)
3.3.2 Case 2
77(5)
3.3.3 Case 3
82(1)
3.4 Assessment of Response to Neoadjuvant Chemotherapy
82(19)
3.4.1 Case 1
82(5)
3.4.2 Case 2
87(11)
3.4.3 Case 3
98(3)
3.5 Post-operative Follow-Up
101(6)
3.5.1 Case 1
101(2)
3.5.2 Case 2
103(2)
3.5.3 Case 3
105(2)
3.6 Use of CEM for High and Indeterminate Risk Screening
107(10)
3.6.1 Case 1
107(8)
3.6.2 Case 2
115(1)
3.6.3 Case 3
115(2)
3.7 CEM VS MRI
117(4)
3.7.1 General Information/Clinical Presentation
117(1)
3.7.2 Recombined Images Analysis
117(1)
3.7.3 MRI Analysis
117(3)
3.7.4 Histopathology
120(1)
References
121(2)
4 Benign Lesions
123(64)
4.1 Cysts
123(5)
4.1.1 Case 1 Cysts
123(4)
4.1.2 Case 2 Cysts
127(1)
4.1.3 Case 3 Inflamed Cyst
128(1)
4.2 Fibrocystic Changes
128(4)
4.2.1 Case 1 Fibrocystic Changes
128(1)
4.2.2 Case 2 Fibrocystic Changes
129(3)
4.2.3 Case 3 Complex Sclerosing Nodule
132(1)
4.3 Tubular Adenoma
132(2)
4.4 Fibroadenoma
134(17)
4.4.1 Case 1 Fibroadenoma
134(3)
4.4.2 Case 2 Fibroadenoma
137(1)
4.4.3 Case 3 Right Fibroadenoma with Left IDC
137(7)
4.4.4 Case 4 Left Breast Fibroadenoma
144(1)
4.4.5 Case 5 Multiple Fibroadenomas
145(6)
4.5 Fibroadenolipoma
151(2)
4.6 Stromal Fibrosis
153(3)
4.6.1 Another Case of Stromal Fibrosis with Different CEM Appearance
155(1)
4.7 Perilobular Haemangioma
156(2)
4.8 Pseudoangiomatous Stromal Hyperplasia (PASH)
158(2)
4.9 Inflammatory Diseases of the Breast
160(24)
4.9.1 Case 1 Non-specific Mastitis
161(4)
4.9.2 Case 2 Acute Suppurative Inflammatory Pathology
165(4)
4.9.3 Case 3 Productive Sclerotic Inflammation
169(4)
4.9.4 Case 4 Abscess
173(3)
4.9.5 Case 5 Chronic Inflammatory Changes
176(1)
4.9.6 Case 6 Granulomatous Mastitis
177(4)
4.9.7 Case 7 Granulomatous Lymphadenitis
181(3)
References
184(3)
5 High-Risk Lesions
187(56)
5.1 Atypical Ductal Hyperplasia (ADH)
187(6)
5.1.1 Case 1 Atypical Ductal Hyperplasia (ADH)
187(5)
5.1.2 Case 2 Proliferating Breast Disease with Atypia and Papillary Lesion
192(1)
5.2 Lobular Neoplasia (LN)
193(27)
5.2.1 Case 1 Lobular Neoplasia (LN)
197(3)
5.2.2 Case 2 Lobular Intraepithelial Neoplasia (LN)
200(5)
5.2.3 Case 3 Classical Lobular Neoplasia (LN)
205(2)
5.2.4 Case 4 Lobular Carcinoma In Situ (LCIS)
207(6)
5.2.5 Case 5 Lobular Carcinoma in Situ, Classic Type
213(7)
5.3 Papilloma
220(12)
5.3.1 Case 1 Papilloma Without Atypia
221(1)
5.3.2 Case 2 Complex Cystic Mass: Papilloma
222(1)
5.3.3 Case 3 Intraductal Papillomas
222(5)
5.3.4 Case 4 Intraductal Papilloma
227(3)
5.3.5 Case 5 Intraductal Papilloma
230(2)
5.4 Radial Scar
232(2)
5.4.1 Case 1 Radial Scar
234(1)
5.5 Phyllodes
234(7)
5.5.1 Case 1 Phyllodes
235(1)
5.5.2 Case 2 Borderline Phyllodes
236(5)
References
241(2)
6 Malignant Lesions
243(122)
6.1 Ductal Carcinoma In Situ (DCIS)
243(8)
6.1.1 Case 1 High-Grade DCIS
243(1)
6.1.2 Case 2 High-Grade DCIS
244(1)
6.1.3 Case 3 High-Grade DCIS
245(1)
6.1.4 Case 4 High-Grade DCIS
246(5)
6.2 Invasive Ductal Carcinoma (IDC)
251(47)
6.2.1 Case 1 IDC with DCIS and ADH
252(5)
6.2.2 Case 2 Right: DCIS Solid and Papillary Type; Left: IDC
257(3)
6.2.3 Case 3 Left IDC + Extensive DCIS; Right: Multifocal Low-Grade DCIS
260(8)
6.2.4 Case 4 IDC, Papillary Lesion, Fibrocystic Disease
268(1)
6.2.5 Case 5 IDC
268(4)
6.2.6 Case 6 IDC
272(5)
6.2.7 Case 7 IDC
277(2)
6.2.8 Case 8 IDC
279(1)
6.2.9 Case 9 Multifocal Invasive Breast Carcinoma of No Special Type (NST) and DCIS
280(5)
6.2.10 Case 10 IDC and DCIS
285(1)
6.2.11 Case 11 IDC and DCIS
286(1)
6.2.12 Case 12 Invasive Breast Carcinoma
287(4)
6.2.13 Case 13 Invasive Breast Carcinoma of No Special Type (NST)
291(6)
6.2.14 Case 14 Invasive Breast Carcinoma of No Special Type (NST)
297(1)
6.3 Malignant Change: Tubular Carcinoma
298(5)
6.4 Malignant Change: Papillary Carcinoma
303(17)
6.4.1 Case 1 Encapsulated Papillary Carcinoma
303(1)
6.4.2 Case 2 Ductal Carcinoma with Encapsulated Papillary Components
304(6)
6.4.3 Case 3 Papillary Carcinoma
310(4)
6.4.4 Case 4 IDC, Papillary Type
314(2)
6.4.5 Case 5 Right: IDC Solid Papillary Type; Left: IDC Mucinous Type
316(4)
6.5 Malignant Change: IDC, Mucinous Carcinoma
320(13)
6.5.1 Case 1 Mucinous Carcinoma
321(1)
6.5.2 Case 2 Mucinous Carcinoma
322(3)
6.5.3 Case 3 Mucinous Carcinoma
325(3)
6.5.4 Case 4 Mucinous Carcinoma
328(4)
6.5.5 Case 5 Mucinous Carcinoma with Axillary Metastases
332(1)
6.6 Malignant Change: Medullary Carcinoma
333(2)
6.6.1 Medullary Carcinoma
334(1)
6.7 Malignant Change: IDC, Apocrine Type
335(1)
6.7.1 Case 1 Apocrine Carcinoma
335(1)
6.8 Malignant Change: Invasive Carcinoma, Neuroendocrine Differentiation
336(2)
6.8.1 Case 1 IDC with Neuroendocrine Differentiation
336(2)
6.9 Malignant Change: Inflammatory Carcinoma
338(1)
6.9.1 Case 1 Inflammatory Carcinoma
338(1)
6.10 Paget's Disease
338(4)
6.10.1 Case 1 Paget's Disease
341(1)
6.11 Malignant Changes: Invasive Lobular Carcinoma (ILC)
342(14)
6.11.1 Case 1 Low-Grade Lobular Carcinoma
343(1)
6.11.2 Case 2 Invasive Lobular Carcinoma
344(4)
6.11.3 Case 3 Extensive Lobular
348(4)
6.11.4 Case 4 Invasive Lobular Carcinoma Presented as "Shrinking Breast"
352(1)
6.11.5 Case 5 ILC
353(1)
6.11.6 Case 6 Invasive Lobular Carcinoma
353(1)
6.11.7 Case 7 Multicentric ILC
354(2)
6.12 Malignant Changes: Metaplastic Carcinoma
356(3)
6.12.1 Malignant Changes: Metaplastic Carcinoma with High-Grade Sarcomatoid Neoplasm
357(2)
6.13 Malignant Changes: Cystosarcoma Phyllodes
359(1)
6.13.1 Case 1 Cystosarcoma Phyllodes
359(1)
6.14 Malignant Changes: Spindle Cell Carcinoma
360(1)
6.14.1 Case 1 Spindle Cell Tumour
360(1)
6.15 Malignant Changes: Metastases
361(2)
6.15.1 Case 1 Metastases from Neuroendocrine Tumour
362(1)
References
363(2)
7 Artefacts and Pitfalls
365(52)
7.1 Artefacts Visible in Both CEM and FFDM Images
365(6)
7.1.1 Case 1 Motion Artefact
365(1)
7.1.2 Case 2 Hair Artefact
365(1)
7.1.3 Case 3 Antiperspirant
366(3)
7.1.4 Case 4 Air-Trapping
369(2)
7.2 Contrast-Related Factors
371(2)
7.2.1 Contrast Splatter
371(2)
7.2.2 Retention of Contrast in Blood Vessels
373(1)
7.3 CEM-Related Factors
373(22)
7.3.1 Breast Within Breast
373(4)
7.3.2 Clip Artefact
377(6)
7.3.3 Air Gap
383(2)
7.3.4 Cutaneous Keratoses
385(1)
7.3.5 Negative Contrast Artefact
386(9)
7.4 Limitations of CEM
395(5)
7.4.1 Limitation: Prosthesis
395(5)
7.4.2 Limitation: Posterior Masses
400(1)
7.4.3 Limitation: Lymph Nodes
400(1)
7.5 Pitfalls in CEM
400(2)
7.5.1 Case 1 Post-biopsy Changes Mimicking Malignant Enhancement-False Positive
400(2)
7.5.2 Case 2 Lobular Carcinoma with Negative CEM and Positive MRI-False Negative
402(1)
7.6 Background Parenchymal Enhancement
402(14)
7.6.1 Background Parenchymal Enhancement
406(5)
7.6.2 Marked Background Parenchymal Enhancement
411(1)
7.6.3 Worse BPE on Second Week Compared with Third Week
411(5)
References
416(1)
8 Intervention and Post-intervention Changes
417(1)
8.1 CEM-Guided Biopsy
417(8)
8.1.1 General Information/Clinical Presentation
417(1)
8.1.2 Mammography Analysis
417(1)
8.1.3 Recombined Images Analysis
417(6)
8.1.4 MRI Analysis
423(1)
8.1.5 CEM Biopsy Guidance Technique
423(1)
8.1.6 Histopathology
423(2)
8.2 Foreign Body Granuloma
425(4)
8.3 Fat Necrosis
429(5)
8.3.1 Case 1
430(2)
8.3.2 Case 2
432(2)
8.4 Post-biopsy Haematoma
434(1)
8.4.1 Case 1 Post-biopsy Haematoma
434(1)
8.5 Recurrent Invasive Malignancy
435(5)
8.5.1 Case 1
438(2)
8.5.2 Case 2
440(1)
8.6 Breast Cancer Infiltration of Dermal Stroma
440(12)
8.6.1 Case 1 Breast Cancer Infiltration of Dermal Stroma
440(3)
8.6.2 Case 2 Breast Cancer Infiltration of Dermal Stroma
443(9)
References
452
Correction to: Atlas of Contrast-Enhanced Mammography 1(452)
Index 453
 

Jacopo Nori is a Consultant Breast Radiologist and the Chief of Breast Imaging at Careggi University Hospital, Italy. His practice specializes in Breast Cancer Imaging, which he has previously trained for and practiced at the Institute Gustave Roussy in Paris, Montpellier Hospital, and Memorial Sloan Kettering Cancer Center in New York.

In addition to Breast Tomosynthesis, Magnetic Resonance Imaging and Contrast-Enhanced Breast Imaging, Dr. Noris interests include laser ablation of breast lesions and B3 lesion removal with VABB systems.





He has authored and co-authored numerous abstracts and publications in national and international journals, as well as three imaging books.









Maninderpal Kaur is a Breast Imaging Radiologist at the Department of Radiology in Tengku Ampuan Rahimah Hospital, Malaysia.  Her undergraduate training was obtained in Bangalore University, India, while she did her postgraduate radiology training at University Malaya in Malaysia.   She pursued a Fellowship in Womens Imaging under the Ministry of Health Malaysia. She was trained in breast imaging at the Gustave Roussy Cancer Institute, Paris, France and Careggi University Hospital, Firenze, Italy.





She has been instrumental in pioneering contrast-enhanced breast imaging in Malaysia. Editor of the first book on Contrast-Enhanced Digital Mammography, she also has a keen interest in the field of research and is an author and co-author in several abstracts and publications in international journals and congresses.



















Anat Kornecki graduated with a degree from the Medical School at Tel-Aviv University, and subsequently completed Abdominal and Womens Imaging fellowships at the University of Toronto. She is currently an Associate Professor at the Department of Medical Imaging, Western University in London, Ontario, Canada. She is the Head of the Breast Imaging division, as well as a Scientist Associate at Lawson and Robarts research institutes, and Regional Lead for breast imaging at Cancer Care Ontario.





J. Devi Meenal is a Professor and Head of the Department of Radio Diagnosis at Government Kilpauk Medical College, Chennai, India. She completed her Radiology residency from Barnard Institute of Radiology, Madras Medical College, Chennai.  Her main research interest and publications focus on womens imaging, with a special interest on MR Mammography and Contrast enhanced Digital Mammography. She has authored 15 publications, and given hundreds of lectures in state and national forums. She has received numerous distinguished orations and citation awards at various national forums for her contribution in the field of Radiology, to name a few - Prof. TS Swaminathan young achiever award, Distinguished alumni award of PSG institutions, Best Performance Award of Appreciation 2017 and Best Doctor Award 2019 from the government of Tamil Nadu.





Martin Yaffe, a medical physicist, is Professor of Medical Biophysics at The University of Toronto and Senior Scientist at Sunnybrook Health Sciences Centre, Toronto, Canada. His team helped pioneer the development and clinical evaluation of digital mammography and the establishment of quantitative measures of mammographic density as a risk factor for breast cancer.  He has published over 290 peer-reviewed articles. His contributions in breast cancer research were recognized by the award of Membership in The Order of Canada in 2015. He is part of the leadership team on the 165,000 woman TMIST randomized trial of breast tomosynthesis.